BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19178759)

  • 1. Review: doxorubicin delivery systems based on chitosan for cancer therapy.
    Tan ML; Choong PF; Dass CR
    J Pharm Pharmacol; 2009 Feb; 61(2):131-42. PubMed ID: 19178759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
    Yu JM; Li YJ; Qiu LY; Jin Y
    J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model.
    Tan ML; Friedhuber AM; Dunstan DE; Choong PF; Dass CR
    Biomaterials; 2010 Jan; 31(3):541-51. PubMed ID: 19836833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin.
    Zhang J; Chen XG; Sun GZ; Huang L; Cheng XJ
    Colloids Surf B Biointerfaces; 2010 Jun; 77(2):125-30. PubMed ID: 20172698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma.
    Ta HT; Dass CR; Larson I; Choong PF; Dunstan DE
    Biomaterials; 2009 Jul; 30(21):3605-13. PubMed ID: 19345993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.
    Bilensoy E; Sarisozen C; Esendağli G; Doğan AL; Aktaş Y; Sen M; Mungan NA
    Int J Pharm; 2009 Apr; 371(1-2):170-6. PubMed ID: 19135514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin.
    Zhang J; Chen XG; Li YY; Liu CS
    Nanomedicine; 2007 Dec; 3(4):258-65. PubMed ID: 17962086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and cytotoxicity of doxorubicin loaded in self-assembled bio-polyelectrolyte microshells.
    Tao X; Chen H; Sun XJ; Chen JF; Roa WH
    Int J Pharm; 2007 May; 336(2):376-81. PubMed ID: 17223293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer, chitosan nanoparticles and catalytic nucleic acids.
    Tan ML; Choong PF; Dass CR
    J Pharm Pharmacol; 2009 Jan; 61(1):3-12. PubMed ID: 19126291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
    Tan ML; Friedhuber AM; Dass CR
    J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
    Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
    Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core-modified chitosan-based polymeric micelles for controlled release of doxorubicin.
    Ye YQ; Yang FL; Hu FQ; Du YZ; Yuan H; Yu HY
    Int J Pharm; 2008 Mar; 352(1-2):294-301. PubMed ID: 18096336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of simple chitosan sheet as drug delivery carrier.
    Saito K; Fujieda T; Yoshioka H
    Eur J Pharm Biopharm; 2006 Oct; 64(2):161-6. PubMed ID: 16884897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulation of antitumor drug Doxorubicin and its analogue by chitosan nanoparticles.
    Sanyakamdhorn S; Agudelo D; Tajmir-Riahi HA
    Biomacromolecules; 2013 Feb; 14(2):557-63. PubMed ID: 23305154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
    Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
    Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive review on alginate-based delivery systems for the delivery of chemotherapeutic agent: Doxorubicin.
    Lakkakula JR; Gujarathi P; Pansare P; Tripathi S
    Carbohydr Polym; 2021 May; 259():117696. PubMed ID: 33673985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy.
    Wang C; Cheng L; Liu Z
    Biomaterials; 2011 Feb; 32(4):1110-20. PubMed ID: 20965564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin.
    Hu FQ; Wu XL; Du YZ; You J; Yuan H
    Eur J Pharm Biopharm; 2008 May; 69(1):117-25. PubMed ID: 17997293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers.
    Gardikis K; Tsimplouli C; Dimas K; Micha-Screttas M; Demetzos C
    Int J Pharm; 2010 Dec; 402(1-2):231-7. PubMed ID: 20934501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.